Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (February 2020)

40 slides from Sorrento Therapeutics's investor presentation, Feb 27, 2020

  1. Slide 1: Significant Life-Changing Medicine

    Sorrento Therapeutics SRNE(NASDAQ) Significant Life-Changing Medicine February 2020 © 2020 Sorrento Therapeutics, Inc. All Rights Reserved 1

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company” or “Sorrento”) and of any of its affiliates, along with certain statements that may be made by management of the Company

  3. Slide 3: Sorrento Therapeutics

    Sorrento Therapeutics Non-Opioid Pain Management Immuno-Oncology & Anti-Viral Plunger Rod Polystyrine Plunger Stopper West 4432/50 Gray Luer-LokTM Adapter Polycarbonate Syringe Burrel, 2.25-mL Type I Glass Syringe Tip Stopper West 7725/65 Gray Light Chain Heavy Chain Fab Hinge TM © 2020 Sorrento The

  4. Slide 4: Sorrento Programs with Blockbuster Potential

    Sorrento Programs with Blockbuster Potential Sorrento Therapeutics Non-Opioid Pain Management Immuno-Oncology & Anti-Viral Therapy Resiniferatoxin (“RTX”), a toxin that ablates afferent nerves Knee replacement deferment + Osteoarthritis knee pain + Terminal Cancer Pain. Multiple phase 3 studies expe

  5. Slide 5: Resiniferatoxin (RTX)

    Resiniferatoxin (RTX) Aβ fiber Aδ fiber C fiber © 2020 Sorrento Therapeutics, Inc. All Rights Reserved

  6. Slide 6: Resiniferatoxin (RTX) Development Priorities

    Resiniferatoxin (RTX) Development Priorities Sorrento Therapeutics Platform Program Pre-IND IND Phase ½ Pivotal NDA Upcoming Milestones Non-opioid Pain Management Knee Replacement Deferment (Potential fast-track) Knee OsteoarthritisPain (Lead Program) Terminal CancerPain (Orphan designation) 2020 Ta

  7. Slide 7: RTX: A Novel Analgesic Approach to Osteoarthritis Pain

    Resiniferatoxin (RTX): A Novel Analgesic Approach to Osteoarthritis Pain (OA) Sorrento TherapeuticsPhase 1b double-blinded, placebo controlled study to assess the safety and preliminary efficacy of intra-articular administration of resiniferatoxin or saline control (as placebo group) for the treatme

  8. Slide 8: RTX OA Knee Pain Phase 1b Trial Update (94 patients)

    RTX OA Knee Pain Phase 1b Trial Update (94 patients) Sorrento Therapeutics No Dose Limiting Toxicities (DLTs) Treatment Emergent Adverse Events (TEAEs) Expected.Moderate. Resolved in less than a day (post-injection pain, tachycardia/hypertension) Efficacy Outcomes Therapeutic signal confirmed in exp

  9. Slide 9: RTX: A Novel Analgesic Approach to Intractable Cancer Pain

    Resiniferatoxin (RTX): A Novel Analgesic Approach to Intractable Cancer Pain Sorrento TherapeuticsA Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin (RTX) Injection for Treatment of Intractable Pain Associated with Cance

  10. Slide 10: Cancer Pain Phase 1b Trial Update (14 patients)

    Cancer Pain Phase 1b Trial Update (14 patients) Sorrento Therapeutics No Dose Limiting Toxicities (DLTs) Treatment Emergent Adverse Events (TEAEs) Expected. Moderate. Transient procedural pain. AE associated with disease progression Efficacy Outcomes Therapeutic signal confirmed in expansion cohorts

  11. Slide 11: Scilex SP-102

    SPSCILEX ¢ NS SP-102

  12. Slide 12: Steroid Formulation to Treat Sciatica Pain (SP-102)

    Steroid Formulation to Treat Sciatica Pain (SP-102)If approved, could become 1stFDA approved steroid for epidural administration (non-compounded drug) for the treatment of sciatica. Potent steroid (dexamethasone sodium phosphate gel). Non-opioid and non-addictive. Well-tolerated. Long history of use

  13. Slide 13: Sorrento Immuno-Oncology Toolbox (proprietary)

    Sorrento Immuno-Oncology Toolbox (proprietary)

  14. Slide 14: Dimeric Antigen Receptor (DAR) Overview

  15. Slide 15: Current CAR-T Technology

    Current CAR-T TechnologyscFvVHVLCAR-TCD3.HingeTM

  16. Slide 16: Autologous CAR-T Process

    to Autologous CAR-T Process sorlen 3 > +n teutopheret lomohoot colecton Teeoctvtion CAR-T - oh

  17. Slide 17: From CAR to DAR

    From CAR to DAR TMscFvFabTMChimeric Antigen Receptor (CAR) scFv-basedDimeric Antigen Receptor (DAR) Fab-based linkerHingeDisulfide bond

  18. Slide 18: The Next-Gen Dimeric Antigen Receptor (DAR) Technology

    The Next-Gen Dimeric Antigen Receptor (DAR) TechnologyFabLight chainHeavy Chain41BBCD3.DARHingeTMDimeric Antigen Receptor

  19. Slide 19: Allogeneic "Off-the-Shelf" KOKI DAR-T Process

    Allogeneic “Off-the-Shelf” KOKI DAR-T Process sorrento i the shelf DAR-T cell therapy doses Lend ‘ellexpansion —_ hon — > > i aren Healthy Donor

  20. Slide 20: Host Cells and Source Materials

    Host Cells and Source MaterialsNK CellsT Cellsaß .d CELL SOURCE MATERIALS: • ADULT IMMUNE CELLS• PLACENTA• CORD BLOOD

  21. Slide 21: Entry and Integration Strategies: Viral vs Non-Viral

    Entry and Integration Strategies: Viral vsNon-ViralT cellNK cellVIRAL LENTIVIRUS RETROVIRUSNON-VIRAL “KOKI”

  22. Slide 22: Autologous CAR-T vs Allogeneic KOKI DAR-T

    Autologous CAR-T vsAllogeneic KOKI DAR-TCurrent CAR-T TechnologyNext-Gen DAR-T TechnologyXY

  23. Slide 23: Increase stability and potency of DAR vs CAR

    Current CAR-T TechnologyNext-Gen DAR-T TechnologyXYIncrease stability and potency of DAR vs CAR-+

  24. Slide 24: Freedom to choose signaling domains in DAR vs CAR

    Current CAR-T TechnologyNext-Gen DAR-T TechnologyXYFreedom to choose signaling domainsin DAR vs CAR-+

  25. Slide 25: Targeted gene disruption and specific integration using KOKI

    Current CAR-T TechnologyNext-Gen DAR-T TechnologyXYTargeted gene disruption and specific integration of antigen receptor gene using KOKI technology-+

  26. Slide 26: TCR gene disruption using KOKI to enable allogeneic T cell therapy

    Current CAR-T TechnologyNext-Gen DART TechnologyXY-+TCR gene disruption using KOKI technology to enable allogeneic T cell therapy

  27. Slide 27: Sorrento Expertise in Cell Manufacturing

    Sorrento Expertise in Cell Manufacturing27Allogeneic DAR-T Cell Manufacturing

  28. Slide 28: DAR-T Competitive Advantages

    DAR-T Competitive AdvantagesKOKI DAR-TAdvantages of DAR-T over CAR-TAntigen ReceptorDimeric Antigen Receptor (DAR)Increased potency Proprietary constructManufacturingVirus Free –KOKI ProcessFaster development Enhanced clonal expansionCell SourceAllogeneic (healthy donor T cells)“Off-the-Shelf” Centr

  29. Slide 29: In-House CAR-T & DAR-T cGMP Manufacturing Capabilities

    In-House CAR-T & DAR-T cGMP Manufacturing CapabilitiesShorter developmenttimesHundredsofpatient-dosesperyearcurrently; Next-gen off-the-shelf technology can potentiallyextendtotensofthousandsof patient-doses perannumReduced manufacturing leadtimesEnd-to-end qualitycontrolsClean room suites meet ISO7

  30. Slide 30: Liquid Tumors Targeting

    Liquid Tumors Targeting CD38, BCMA, CD20, CD123

  31. Slide 31: Hematological Malignancies in the US

    ematological Malignancies in the USCD19: Novartis (Kymriah™)CD19: Kite (Yescarta™)CD38: Janssen/GenMab (Darzalex®) CD38: Sorrento (CD38 CAR-T) BCMA: Bluebird Bio (bb2121 for BCMA CAR-T)Sources: Global Data Reports, National Cancer Institute Statistics

  32. Slide 32: CD38 Modalities Deployed against Multiple Myeloma

    CD38 Modalities Deployed against Multiple MyelomaIndicationProgramPre-INDINDPhase1PivotalNDAUpcomingMilestonesUpcomingMilestonesMultiple MyelomaCD38CAR-TPhase1dataread-outexpected in 2020CD38ADCINDsubmissionexpected in 2020CD38DAR-T (allogeneic)INDanticipated acceptance in 2020CD38/CD3BsAbINDsubmiss

  33. Slide 33: Anti-CD38 DAR-T Cells more Potent than CD38 CAR-T Cells

    Anti-CD38 DAR-T Cells more Potent than CD38 CAR-T Cells©2018, Sorrento Therapeutics, Inc. All Rights Reserved.©2020SorrentoTherapeutics,Inc.AllRightsReserved

  34. Slide 34: Allogeneic Anti-BCMA DAR-T

    Allogeneic Anti-BCMA DAR-T01020304050607080020406080100Survival Rate and Time ProfileDay Post TreatmentSurvivalRatePBSTCR-KOBCMA DAR (6e6)BCMA DAR (1.2e6)BCMA DAR (2.4e5)3434©2018, Sorrento Therapeutics, Inc. All Rights Reserved. ©2020SorrentoTherapeutics,Inc.AllRightsReserved35

  35. Slide 35: Allogeneic Anti-CD20 DAR-T

    Allogeneic Anti-CD20 DAR-TAnti-CD20 DAR-T cells Eradicate tumor Cells in Daudi Xenograft Mice model and all animal survivedSurvival%

  36. Slide 36: Solid Tumors Targeting

    Dimeric Antigen Receptor (DAR) Solid Tumors Targeting EGFR, GD2, Her2, cMET, CEA,

  37. Slide 37: Allogeneic Anti-GD2 DAR-T

    Allogeneic Anti-GD2 DAR-T sorrento Survival proportions: SK-MEL-5 1004 > pes “TRAC KO nt survival te antiD2-0aR T = T T T ° 20 40 60 Days after T Cell Treatment Efficacy of anti-GD2 DAR T against SK-MEL-5 Human Melanoma Subcutaneous Xenograft General Health Monitor: Survival curve

  38. Slide 38: Virus Targeting

    Virus Targeting COVID-19, HBV, HIV, Influenza

  39. Slide 39: COVID-19 Targeting DAR Construct Rapidly Generated

    COVID-19 Targeting DAR Construct Rapidly Generated sorrento Broad-spectrum anti-coronavirus construct Anti-COVID-19 construct generated within weeks and DAR-T and DAR-NK cells will soon be produced for anti- COVID-19 activity testing IND-enabling studies will be started, while preparing for fast-tra

  40. Slide 40: Seasoned Executive Team

    Seasoned Executive TeamDr Henry Ji Jiong Shao Henry Ji, Ph.D.Chairman, President and Chief Executive OfficerDeborah Telman, J.D.SVP and General CounselJiong Shao, M.B.A.EVP and Chief Financial OfficerImage result for stratagene Image result for lehman brothers logo Image result for macquarie logo Im

Sorrento Therapeutics — Investor Presentation (February 2020) on 6ix